Goldman Sachs forecasts the S&P 500 will stay at around 4,000 in 2023. But opportunities for returns still exist, said a team of strategists. They shared specific sectors and stocks they think will outperform next year. Strategists at Goldman Sachs don’t have much faith in the stock market for 2023. In a note to clients on Monday, the bank’s Chief US Equity Strategist David Kostin and a team of his colleagues put a price target of 4,000 on the S&P 500 for next year, which is right around the index’s current level. Their call assumes the Federal Reserve can achieve a soft landing, where they succeed in bringing down inflation without sending the US economy into a recession. If a recession does unfold, however, Kostin sees the S&P 500 falling to 3,150. Foto: Goldman Sachs Even though his base case is a soft landing, Kostin cited a likely decline in earnings due to rising interest rates as his reasoning for his neutral view for 2023. But while he thinks any return from the broader market is improbable, opportunities still remain, he said.
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #EvercoreISI--Hologic to Webcast Presentation at the 5th Annual Evercore ISI HealthCONx Conference
Hologic exceeded expectations again on the back of stronger COVID-19 testing. Click here to read a full investment analysis of HOLX stock.
Trading Report for Hologic HOLX With Buy and Sell Signals
3Dimensions System Earns Distinction for Meeting or Exceeding Rigorous European Image Quality and Dose Standards Hologic, Inc. (Nasdaq: HOLX), a global leader in women''s health, announced today th…
MITTEILUNG UEBERMITTELT VON BUSINESS WIRE. FUER DEN INHALT IST ALLEIN DAS BERICHTENDE UNTERNEHMEN VERANTWORTLICH.3Dimensions System Earns Distinction for Meeting or Exceeding Rigorous European Image Quality and Dose StandardsMARLBOROUGH, Mass. --(BUSINESS WIRE)-- 03.11.2022 --Hologic, Inc. (Nasdaq: HOLX), a global leader in…
MARLBOROUGH, Mass.--(BUSINESS WIRE)-- #3Dimensions--Hologic’s 3Dimensions™ System for 3D Mammography Receives EUREF Type Test Certification
The money will support research and development to help the company gain FDA approval for its SARS-CoV-2 test and a SARS-CoV-2, influenza A and B, and RSV test.
Hologic (HOLX) on Wednesday said it had got a $19M contract from the Biomedical Advanced Research and Development Authority ((BARDA)) to support research and development efforts
Hologic Announces Contract with BARDA to Support IVD Approval of COVID Assays
Hologic Inc. (NASDAQ:HOLX) traded at $74.13 at close of the session on Tuesday, 11/01/22, made an upward move of 9.34% on its previous day’s price. Looking at the stock we see that its previous close was $67.80 and the beta (5Y monthly) reads 1.09 with the day’s price range being $70.40 – $74.67. The company … Hologic Inc.’s Stock Price Relatively Up Recently, But Trouble Is Still Brewing Read More »
If you''ve never heard of Hologic (NASDAQ: HOLX), then it may be a good time to take a look at this medical equipment maker. The company shot up in today''s trading session. The biggest reason for this surge was Hologic''s impressive earnings report. It brought in $0.82 per share. That''s down substantially against figures from this time last year when the company brought in $1.61 per share. However, it was still well above expectations, as the company easily beat TipRanks projections calling for $0.62 per share. Company officials noted that the company saw "unprecedented strength" across its primary line of businesses. HOLX posted revenue of $953.3 million as well.
Hologic, Inc. (HOLX) gained ~7% pre-market Tuesday as analysts issued favorable views on the COVID-19 test developer’s Q4 fiscal 2022 results that exceeded the company forecasts and…
Hologic Inc (NASDAQ: HOLX ) posted Q4 adjusted EPS of $0.82 , down from $1.61 a year ago and beating the consensus of $0.63. Revenue of $953.3 million decreased 27.6% Y/Y (down 25.6% on constant currency), primarily driven by lower sales of COVID-19 assays and supply chain challenges related to semiconductor chips in … Full story available on Benzinga.com
Gainers: Hologic (HOLX) +8%. TripAdvisor (TRIP) +7%
After-Hours Stock Movers: Hologic, Avis Gain on Results; Goodyear Falls
The shares of Hologic, Inc. (HOLX) spiked in the post-market trading Monday after the healthcare device maker said its financial measures for Q4 fiscal 2022 exceeded expectations even…
Hologic (HOLX) is scheduled to announce Q4 earnings results on Monday, October 31st, after market close.The consensus EPS Estimate is $0.62 (-61.5% Y/Y) and the consensus Revenue…
Google Cloud unveiled a new product suite to make medical imaging data more interoperable and useful via artificial intelligence. Hackensack Meridian Health has begun using it to detect metastasis in prostate cancer patients earlier, and Hologic is using it to strengthen its diagnostic platform that screens women for cervical cancer.
MARLBOROUGH, Mass.--(BUSINESS WIRE)---- $HOLX #earnings--Hologic to Announce Financial Results for the Fourth Quarter of Fiscal 2022 on Monday, October 31, 2022
CNBC''s Jim Cramer interviewed Hologic CEO Steve MacMillan on Monday.